Under the wave of pharmaceutical innovation, pharmaceutical companies are increasing the size of these areas

In recent years, under the guidance of policy and financial impetus, innovative drugs are becoming a heavy military gathering place for Chinese and foreign pharmaceutical companies.
, domestic innovative pharmaceutical enterprises with the help of the capital market, successively refresh the financing record.
, on the other hand, multinational pharmaceutical giants are continuing to add to China's domestic innovation.
, anti-tumor, cardiovascular disease, antiviral, anti-infection and artificial intelligence medicine are becoming the racetrack for all bets.
, three tracks are the focus of the drug companies.
anti-tumor innovative drugs According to the newly released data of the National Cancer Center, the incidence of malignant tumors in China is 285.83 per 100,000, and the mortality rate is 170.05 per 100,000.
the annual morbidity and mortality rates in the United States have increased by 3.9% and 2.5% respectively, and the incidence and death toll are on the rise.
with the increasing number of cancer patients in China, anti-tumor drugs are beginning to face huge clinical needs.
industry estimates that the global cancer drug market is expected to exceed $150 billion by 2020, with sales of prescription drugs exceeding $110 billion.
's huge market demand, coupled with China's drug review and approval reform, to encourage drug innovation, innovative drugs on the market time is constantly shortened, the enthusiasm of domestic innovative drug declaration is also increasing, many enterprises are in the market.
, 2018 is a year of independent research and development of new anti-tumor drugs in China.
has approved 18 innovative anti-tumor drugs, 5 of which have been independently developed in China, including hydrochloric acid atrotinie for the treatment of lung cancer (Zhengda Tianqing), mammoth cancer of pyridoxine (Jiangsu Hengrui) and so on.
, the anti-tumor drug circuit is still the gold track in the eyes of pharmaceutical companies, with more than 2,000 cancer treatment drugs and vaccines in different stages of development worldwide, more than 90% of which are targeted drugs.
in China, in the first half of 2019, CDE hosted 145 newly declared chemical drug species in the field of new drugs, there are 60 declared varieties of anti-tumor drugs, far more than the second-ranked nervous system drugs (23 varieties).
currently, traditional oncology treatments are highly competitive and track-crowded, and it is particularly important to choose an innovative segment, such as Parkinson's disease and Alzheimer's.
After this year's outbreak, the industry is fully aware of the global warming, globalization under the international exchanges more frequent and other factors, the future virus formation cycle may be shorter and shorter, anti-virus, anti-infection areas need to continue to increase research and development investment.
background, the State Drug Administration has also accelerated the introduction of new drugs for imported and domestically produced anti-regenerative immunodeficiency syndrome through a series of policies.
industry believes that in the future in the promotion of health insurance policy, as well as new compound, long-acting drugs for clinical characteristics, antiviral drugs hospital market will usher in rapid development, more and more enterprises will also add code into this area.
July this year, Hengrui announced the establishment of a new company to lay out the field of antivirals.
recent years, how to dig up new drugs, or provide better medical services for patients, is making the rapid development of artificial intelligence technology more and more the focus of the industry.
especially this year, AI's performance in this outbreak has given industry insiders a glimpse of the potential of AI in the medical field.
Industry believes that with the maturation of basic technology conditions such as artificial intelligence calculation and algorithms, the strong support of policies for the development of artificial intelligence technology, and the accumulation of data in the medical market, China is forming a digital medical ecosystem that will provide a powerful impetus for innovation and development in the pharmaceutical industry.
new technologies, products and services are rapidly being rolled out and tested in the Chinese market, and companies are exploring digital solutions to address unseeded consumer needs.
, more and more pharmaceutical companies will choose to apply artificial intelligence technology in order to further save the cost and time of testing, in order to shorten the research and development process, reduce research and development costs, and improve the success rate of new drug research and development.